Table 2. Randomized clinical trial of surgery for esophageal cancers with and without chemotherapy and radiation.
| Reference | Trial | Treatment | Treatment cohort | Patients randomized (no.) | OS 5-yr rate (%) | Disease-free 5-yr rate (%) | R0 resection (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRS | CRS | S | CRS | S | CRS | S | CRS | S | ||||||
| van Hagen P, et al. (2012) (7) | Dutch Cancer Foundation CROSS Trial | Carboplatin + Paclitaxel, concurrent radiation | Esophageal or GEJ cancer or squamous (23%), adenocarcinoma (75%), other (2%) origin. | 178 | 188 | 47 | 34 | _ | _ | 92 | 9 | |||
CRS, neoadjuvant chemoradiotherapy followed by surgery; OS, overall survival; S, surgery alone.